Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Appointed CFO
Quarterly results
CC transcript
Asset disposition
Inv. presentation
Acq. announced
Director departure
MEDICINOVA INC (MNOV) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/22/2021 GN MediciNova Receives Gene Therapy Milestone Payments
04/19/2021 GN MediciNova to Participate in the B. Riley Neuroscience Conference
03/08/2021 GN MediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
03/03/2021 GN MediciNova Announces Update on SARS-CoV-2 Vaccine for COVID-19
01/31/2021 GN MediciNova Announces Closing of US$20 Million Private Placement Transaction
01/18/2021 GN MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan
01/11/2021 GN MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners
12/29/2020 GN MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS
12/15/2020 GN MediciNova Added to the NASDAQ Biotechnology Index
11/25/2020 GN MediciNova Announces Positive Optical Coherence Tomography Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Published in Multiple Sclerosis Journal
11/24/2020 GN MediciNova Announces Initiation of Master Virus Seed Stock Production for its Intranasal COVID-19 Vaccine using BC-PIV Vector Technology
11/12/2020 GN MediciNova Announces Presentation of Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model at The Liver Meeting Digital Experience™ 2020
10/22/2020 GN MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy
10/21/2020 GN MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair
10/13/2020 GN MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020
09/24/2020 GN MediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology
09/23/2020 GN MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector Technology
09/11/2020 GN MediciNova Announces that BioComo's Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against the RS Virus in Mice using BC-PIV Technology
09/01/2020 GN MediciNova Announces Development Progress on Intranasal Formulation of SARS-CoV-2 Vaccine for COVID-19
08/06/2020 GN MediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the American Psychological Association 2020 Annual Convention
08/04/2020 GN MediciNova to Participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
07/27/2020 GN MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan
07/20/2020 GN MediciNova to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit
07/01/2020 GN MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) for Prevention of Acute Respiratory Distress Syndrome in Patients with COVID-19
06/25/2020 GN MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology
06/23/2020 GN MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Europe
04/20/2020 GN MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
04/08/2020 GN MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
03/09/2020 GN MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS)
02/17/2020 GN MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan
01/27/2020 GN MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe
12/04/2019 GN MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia
09/30/2019 GN MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China
09/11/2019 GN MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New York
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy